The BRINSUPRI launch trajectory is accelerating far ahead of expectations, driving a rapid path to profitability. Traders should watch for continued prescription growth data and the upcoming regulatory decision for brensocatib in Japan, which could further boost the stock. The raised peak revenue estimates to >$14B provide a long-term valuation anchor.
Drugs in focus
INSM drug pipeline →ARIKAYCE
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed since 2018. Label expansion decision pending FDA review (sNDA submitted July 2026, no specific PDUFA date available).
- Next catalyst
- PDUFA date · Jan 28, 2027 73d
What to watchARIKAYCE is a mature commercial asset for Insmed; the stock's primary driver is now BRINSUPRI's launch trajectory. Investors should watch for the FDA decision on ARIKAYCE's sNDA for label expansion to newly diagnosed MAC patients (timing unconfirmed), but the bigger stock-moving events will likely be BRINSUPRI sales updates and the Japan approval ramp.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $132.55entry
- T+1 · 3mo ago −1.09%α −1.71% · $131.10
- T+5 · 3mo ago −4.69%α −5.91% · $126.33
- T+20 · 3mo ago −4.43%α −5.03% · $126.68
- T+60 · 18d ago −15.81%α −14.39% · $111.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estimates of $393.4M, driven by a 49% sequential surge in BRINSUPRI sales to $309.2M. The company raised its full-year BRINSUPRI guidance to $1.25B-$1.4B (from 'at least $1B') and boosted its peak revenue estimate for three lead programs to over $14B. The net loss narrowed dramatically to $13.2M ($0.06/share) from $321.7M ($1.70/share) a year ago, signaling a rapid path to profitability.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $425.5M, up 296% YoY vs $107.4M.
- BRINSUPRI revenue of $309.2M, up 49% sequentially from Q1 2026.
- Full-year 2026 BRINSUPRI guidance raised to $1.25B-$1.40B from 'at least $1B'.
- Peak revenue estimate raised to >$14B combined for BRINSUPRI, TPIP, and ARIKAYCE.
- Net loss narrowed to $13.2M ($0.06/share) from $321.7M ($1.70/share) in Q2 2025.
- Cash, cash equivalents, and marketable securities of ~$1.2B as of June 30, 2026.
- sNDA submitted to FDA in July for ARIKAYCE label expansion to newly diagnosed MAC lung disease patients.
- Positive 12-month OLE data for TPIP in PAH reported in July 2026.
Financial Impact
Revenue beat consensus by $32.1M (+8.2%); EPS of -$0.06 was a massive beat vs consensus of -$0.68; BRINSUPRI guidance raised by $250M-$400M at the midpoint.
Risk Factors
- Execution risk in sustaining BRINSUPRI's rapid launch trajectory.
- Regulatory risk for ARIKAYCE label expansion and brensocatib approval in Japan.
- High R&D and SG&A spending as the company invests in pipeline and commercial infrastructure.
- Dependence on a single product (BRINSUPRI) for near-term growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-031502 |
| Document: ef20079469_ex99-2.htm | 0001140361-26-031502 |
| Document: ef20079469_8k.htm | 0001140361-26-031502 |
| Document: 0001140361-26-031502-index-headers.html | 0001140361-26-031502 |
| Document: 0001140361-26-031502-index.html | 0001140361-26-031502 |
| Document: 0001140361-26-031502.txt | 0001140361-26-031502 |
| 8-K Data (Synthetic) | 0001140361-26-031502 |
Track record
24 reports on INSM
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Viewing Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers